| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) (NCT05263999) | Equillium | 2022-04-29 |
| Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) (NCT05289167) | Northwell Health | 2022-03-13 |
| Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis (NCT05158608) | National Research Center for Hematology, Russia | 2022-01-01 |
| PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis (NCT04886726) | Henry Ford Health System | 2021-12-23 |
| Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation (NCT04838704) | Zhejiang University | 2021-04-01 |
| Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD) (NCT04144036) | Sameem M. Abedin, MD | 2020-12-14 |
| A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. (NCT04688021) | Yi Luo | 2020-12-03 |
| Relationship Between "FODMAPs" and "GVHD" (NCT04660487) | The First Affiliated Hospital of Soochow University | 2020-12-01 |
| Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention (NCT04503616) | NYU Langone Health | 2020-09-16 |
| HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis (NCT03456817) | AHS Cancer Control Alberta | 2020-07-01 |
| Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation (NCT04131738) | Washington University School of Medicine | 2020-04-07 |
| Cryopreservation of White Blood Cells Before Their UVA Irradiation for Graft Versus Host Disease Treatment (NCT03361254) | Central Hospital, Nancy, France | 2020-03-31 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (NCT03842696) | University of Michigan Rogel Cancer Center | 2020-02-04 |
| A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant (NCT04337515) | Christopher Dvorak | 2019-12-19 |
| RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation (NCT04014790) | Regimmune Corporation | 2019-11-25 |
| Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant (NCT03924401) | Emory University | 2019-08-22 |
| Safety and Efficacy of Fecal Microbiota Transplantation (NCT04014413) | Chinese University of Hong Kong | 2019-07-15 |
| Optimizing PTCy Dose and Timing (NCT03983850) | National Cancer Institute (NCI) | 2019-07-09 |
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. (NCT02849886) | Centre Hospitalier Universitaire de Besancon | 2019-04-10 |
| Prevalence of Chronic Oral Graft Versus Host Disease Risk Factors in Pediatric Patients (NCT03880214) | yasmeen magdi sholkamy | 2019-04-01 |
| Itacitinib for Low Risk GVHD (NCT03846479) | John Levine | 2019-03-25 |
| CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (NCT03605927) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-15 |
| Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies (NCT03771222) | Chinese PLA General Hospital | 2019-01-01 |
| Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease (NCT03591874) | Ocugen | 2018-12-23 |
| Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD) (NCT03395340) | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2018-11-19 |
| Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls (NCT03602599) | National Institute of Dental and Craniofacial Research (NIDCR) | 2018-11-15 |
| Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies (NCT03818334) | Hospital Israelita Albert Einstein | 2018-11-06 |
| Cellular Stress Reactions During Graft-versus-host Disease (NCT04558788) | University of Freiburg | 2018-11-01 |
| Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation (NCT03357159) | Sheba Medical Center | 2018-09-06 |
| A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD (NCT03459040) | John Levine | 2018-08-17 |
| Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation (NCT03207958) | Washington University School of Medicine | 2018-05-16 |
| Detection of Graft Versus Host Disease With [18F]F-AraG (NCT03367962) | CellSight Technologies, Inc. | 2018-05-15 |
| Dynamic of Immunocompetent Populations in Patients Treated With Extracorporeal Photopheresis in Chronic Graft Versus Host Disease (NCT03438643) | University Hospital, Lille | 2018-05-07 |
| An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) (NCT03339297) | Jazz Pharmaceuticals | 2018-02-21 |
| Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors (NCT03727113) | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2018-01-16 |
| Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC (NCT03263767) | Nantes University Hospital | 2018-01-15 |
| Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients (NCT04290429) | University of Freiburg | 2017-12-06 |
| Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant (NCT03102060) | Rutgers, The State University of New Jersey | 2017-08-22 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT03192397) | Roswell Park Cancer Institute | 2017-08-09 |
| Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT) (NCT03148197) | University of Cologne | 2017-07-14 |
| Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis (NCT03204721) | Oslo University Hospital | 2017-06-21 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT (NCT03395860) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2017-05-30 |
| The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation (NCT03147157) | The First Hospital of Jilin University | 2017-05-01 |
| A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD (NCT02956122) | Baxalta now part of Shire | 2017-04-26 |
| Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant (NCT03297528) | Peking University People's Hospital | 2017-03-01 |
| Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD (NCT02561520) | Ladan Espandar | 2016-12-01 |
| CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT (NCT02942173) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2016-10-01 |
| Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE) (NCT02080195) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-09-13 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease (NCT02867800) | Monica Bhatia | 2016-07-01 |
| Early Detection of Mucosal Abnormalities in Graft-versus-host Disease (NCT02707354) | Nantes University Hospital | 2016-06-03 |
| Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT (NCT02812940) | University of Cologne | 2016-04-01 |
| Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention (NCT02588339) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-04 |
| Tocilizumab for Chronic Graft-versus-Host Disease Treatment (NCT02174263) | Fred Hutchinson Cancer Center | 2016-02-01 |
| Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT) (NCT03419078) | Imperial College Healthcare NHS Trust | 2015-12-01 |
| Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant (NCT02526329) | Everett Meyer | 2015-08-06 |
| Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair (NCT02483702) | Valley Anesthesiology Consultants | 2015-08-01 |
| Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation (NCT02342613) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-05-28 |
| Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT (NCT02398708) | University of Florida | 2015-05-01 |
| CINC424A2X01B Rollover Protocol (NCT02386800) | Novartis Pharmaceuticals | 2015-03-05 |
| Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases (NCT02248597) | Wake Forest University Health Sciences | 2015-02-25 |
| Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids (NCT02379442) | National Heart, Lung, and Blood Institute (NHLBI) | 2015-02-23 |
| Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease (NCT01988701) | Ohio State University Comprehensive Cancer Center | 2015-02-01 |
| Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD (NCT02824653) | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 2015-01-01 |
| BMT Autologous MSCs for GvHD (NCT02359929) | Emory University | 2015-01-01 |
| Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD (NCT02176031) | Dana-Farber Cancer Institute | 2015-01-01 |
| Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD (NCT02322190) | National Cancer Institute (NCI) | 2014-12-20 |
| Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease (NCT02203578) | Rutgers, The State University of New Jersey | 2014-11-01 |
| Carfilzomib for the Prevention of Graft Versus Host Disease (NCT01991301) | Sheba Medical Center | 2014-11-01 |
| Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease (NCT01795573) | H. Lee Moffitt Cancer Center and Research Institute | 2014-10-29 |
| Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) (NCT02193880) | Ayman Saad | 2014-10-09 |
| Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies (NCT02145403) | University of Michigan Rogel Cancer Center | 2014-10-01 |
| Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE) (NCT02151539) | Vanderbilt-Ingram Cancer Center | 2014-08-29 |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease (NCT02195869) | Pharmacyclics LLC. | 2014-07-14 |
| Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant (NCT02109809) | Wake Forest University Health Sciences | 2014-07-01 |
| Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT (NCT02144025) | Hospital Universitario Dr. Jose E. Gonzalez | 2014-05-01 |
| Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation (NCT02799888) | Affiliated Hospital to Academy of Military Medical Sciences | 2014-04-01 |
| Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT (NCT02086513) | Massachusetts General Hospital | 2014-04-01 |
| In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis (NCT01927120) | H. Lee Moffitt Cancer Center and Research Institute | 2014-03-25 |
| Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease (NCT02055625) | Karolinska Institutet | 2014-01-01 |
| Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease (NCT02194439) | Indiana University | 2014-01-01 |
| Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD (NCT01911039) | Laura Johnston | 2013-07-01 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research (NCT01851382) | National Cancer Institute (NCI) | 2013-05-15 |
| G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation (NCT01857336) | Peking University People's Hospital | 2013-03-01 |
| Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant (NCT02144701) | Rutgers, The State University of New Jersey | 2013-02-18 |
| Clinical and Biomarker Study of the Efficacy of Extracorporeal Photopheresis in Graft-versus-host Disease (NCT03124056) | Fundación para la Investigación del Hospital Clínico de Valencia | 2013-01-10 |
| Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant (NCT01754389) | Dana-Farber Cancer Institute | 2013-01-01 |
| Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host (NCT02891395) | University Hospital, Lille | 2012-12-24 |
| Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease (NCT01616680) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2012-09-01 |
| Pomalidomide for Chronic Graft-versus-Host Disease (NCT01688466) | National Cancer Institute (NCI) | 2012-08-30 |
| Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation (NCT01596075) | Rabin Medical Center | 2012-07-01 |
| Bortezomib in Patients With Chronic Graft Versus Host Disease (NCT01672229) | Mehrdad Abedi, MD | 2012-07-01 |
| Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease (NCT01616056) | Fred Hutchinson Cancer Center | 2012-06-01 |
| Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD (NCT02511782) | Children's Hospital Medical Center, Cincinnati | 2012-02-01 |
| Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease (NCT01485055) | Nationwide Children's Hospital | 2011-12-01 |
| Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications (NCT01633229) | National Heart, Lung, and Blood Institute (NHLBI) | 2011-11-14 |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers (NCT01240525) | University College, London | 2011-11-01 |
| Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment (NCT01460914) | Dartmouth-Hitchcock Medical Center | 2011-10-01 |